Jin H*, Gulhan DC*, Geiger B, Ben-Isvy D, Geng D, Ljungström V, Park PJ. Accurate and sensitive mutational signature analysis with MuSiCal. Nat Genet. 2024
Gulhan DC, Viswanadham V, Muyas F, Jin H, Foote MB, Lee JJ, Barras D, Jung YL, Ljungstrom V, Rousseau B, Galor A, Diplas BH, Maron SB, Cleary JM, Cortés-Ciriano I, Park PJ medRxiv 2024.01.19.24301236; doi: https://doi.org/10.1101/2024.01.19.24301236
Batalini F*, Gulhan DG*, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin Cancer Res (2022) 28 (21): 4714–4723.
Cortés-Ciriano I, Gulhan DC, Lee JJ, Melloni GEM, Park PJ Computational analysis of cancer genome sequencing data. Nat Rev Genet. 2021 Dec 8
Gulhan DC, Garcia E, Lee EK, Lindemann NI, Liu JF, Matulonis UA, Park PJ, Konstantinopoulos PA. Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020;4:492-497.
Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 Mar 19;11(1):1459.
Gulhan DC, Lee JJ, Meloni GEM, Cortes Cirano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples, Nat Genet. 2019 May;51(5):912-919.
